Jean-Pierre Sommadossi - 31 Jan 2022 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role
President, CEO, and Chairman, Director
Signature
/s/ Andrea Corcoran, as Attorney-in-Fact for Jean-Pierre Sommadossi, Andrea Corcoran, as Attorney-in-Fact for Jean-Pierre Sommadossi
Issuer symbol
AVIR
Transactions as of
31 Jan 2022
Net transactions value
$0
Form type
4
Filing time
02 Feb 2022, 16:15:38 UTC
Previous filing
30 Jun 2021
Next filing
02 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVIR Stock Option (Right to Buy) Award $0 +378,033 $0.000000 378,033 31 Jan 2022 Common Stock 378,033 $7.14 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2022.